Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies

Last updated: March 25, 2025
Sponsor: University Hospital, Grenoble
Overall Status: Active - Recruiting

Phase

N/A

Condition

Pressure Ulcers

Treatment

Isolation of anti-Pseudomonas antibodies from type B lymphocytes

Clinical Study ID

NCT04335383
38RC20.048
2020-A00311-38
  • Ages > 18
  • All Genders

Study Summary

Pseudomonas aeruginosa is a pathogenic bacteria for human, especially in hospital settings. It can sometimes be multi-resistant to many or even to all antibiotics usually used for its treatment.

The aim of the study is to isolate and produce therapeutic antibodies against the bacteria Pseudomonas aeruginosa in order to provide an alternative treatment to antibiotics in case of infection with an antibiotic-resistant strain of Pseudomonas aeruginosa.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient selected in the retrospective part of the study (patient with serumcontaining functional anti-Pseudomonas aeruginosa antibodies)

  • Patient with weight ≥ 32kg.

  • With a follow-up visit at Grenoble University Hospital with a blood sampling for itscare

  • Having given its written no objection to participate in the prospective phase ofthis project

Exclusion

Exclusion Criteria:

  • Legally protected patient (minor, pregnant or nursing woman, ward or ward curated,hospitalized under duress or deprived of liberty)

Study Design

Total Participants: 10
Treatment Group(s): 1
Primary Treatment: Isolation of anti-Pseudomonas antibodies from type B lymphocytes
Phase:
Study Start date:
October 05, 2020
Estimated Completion Date:
October 31, 2025

Connect with a study center

  • Chu Grenoble Alpes

    Grenoble, 38043
    France

    Active - Recruiting

+−

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.